News

Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...
The Lancet17h
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
aDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA bDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ...